Microsatellite instability in melanoma: A comprehensive review

Melanoma Research

Volumn 26, Issue 6, 2016, Pages 545-550

  Kubeček, Ondřej ^a   Kopecký, Jindřich ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

DNA mismatch repair; drug resistance; immunotherapy; melanoma; microsatellite instability; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CLINICAL FEATURE; CUTANEOUS MELANOMA; HUMAN; MELANOMA; MICROSATELLITE INSTABILITY; MUCOSAL MELANOMA; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; UVEA MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; MISMATCH REPAIR; PROCEDURES; SKIN TUMOR;

DNA MISMATCH REPAIR; HUMANS; IMMUNOTHERAPY; MELANOMA; MICROSATELLITE INSTABILITY; SKIN NEOPLASMS;

EID: 84987680071     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000298     Document Type: Review

References (44)

1. Richman S. Deficient mismatch repair: read all about it (review). Int J Oncol 2015; 47: 1189-1202.
2. Reuschenbach M, Sommerer C, Hartschuh W, Zeier M, Doeberitz M, Kloor M. Absence of mismatch repair deficiency-related microsatellite instability in non-melanoma skin cancer. J Invest Dermatol 2012; 132: 491-493.
3. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008; 17: 3208-3215.
4. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 2011; 135: 1269-1277.
5. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
6. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.
7. Kroiss MM, Vogt TM, Schlegel J, Landthaler M, Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venereol 2001; 81: 242-245.
8. Talwalkar VR, Scheiner M, Hedges LK, Butler MG, Schwartz HS. Microsatellite instability in malignant melanoma. Cancer Genet Cytogenet 1998; 104: 111-114.
9. Peris K, Keller G, Chimenti S, Amantea A, Kerl H, Höfler H. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol 1995; 105: 625-628.
10. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996; 56: 589-593.
11. Tomlinson IP, Beck NE, Bodmer WF. Allele loss on chromosome 11q and microsatellite instability in malignant melanoma. Eur J Cancer 1996; 32A: 1797-1802.
12. Hussein MR, Sun M, Tuthill RJ, Roggero E, Monti JA, Sudilovsky EC, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001; 28: 343-350.
13. Richetta A, Silipo V, Calvieri S, Frati L, Ottini L, Cama A, Mariani-Costantini R. Microsatellite instability in primary and metastatic melanoma. J Invest Dermatol 1997; 109: 119-120.
14. Birindelli S, Tragni G, Bartoli C, Ranzani GN, Rilke F, Pierotti MA, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2000; 86: 255-261.
15. Palmieri G, Ascierto PA, Cossu A, Colombino M, Casula M, Botti G, et al. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 2003; 13: 167-170.
16. Uribe P, Wistuba II, Solar A, Balestrini C, Perez-Cotapos ML, Gonzalez S. Comparative analysis of loss of heterozygosity and microsatellite instability in adult and pediatric melanoma. Am J Dermatopathol 2005; 27: 279-285.
17. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
18. Massi D, Sardi I, Urso C, Franchi A, Borgognoni L, Salvadori A, et al. Microsatellite analysis in cutaneous malignant melanoma. Melanoma Res 2002; 12: 577-584.
19. Garcia JJ, Kramer MJ, O'Donnell RJ, Horvai AE. Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanoma. Mod Pathol 2006; 19: 950-957.
20. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-1156.
21. Uribe P, Wistuba II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol 2009; 31: 354-363.
22. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982; 13: 123-132.
23. Hussein MR, Haemel AK, Albert DM, Wood GS. Microsatellite instability and alterations of mismatch repair protein expression in choroidal melanomas. Arch Ophthalmol 2005; 123: 1705-1711.
24. Cross NA, Murray AK, Rennie IG, Ganesh A, Sisley K. Instability of microsatellites is an infrequent event in uveal melanoma. Melanoma Res 2003; 13: 435-440.
25. Nakamoto D, Yamamoto N, Takagi R, Katakura A, Mizoe JE, Shibahara T. Detection of microsatellite alterations in plasma DNA of malignant mucosal melanoma using whole genome amplification. Bull Tokyo Dent Coll 2008; 49: 77-87.
26. Marani C, Alvino E, Caporali S, Vigili MG, Mancini G, Rahimi S. DNA mismatch repair protein expression and microsatellite instability in primary mucosal melanomas of the head and neck. Histopathology 2007; 50: 780-788.
27. Alvino E, Marra G, Pagani E, Falcinelli S, Pepponi R, Perrera C, et al. Highfrequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol 2002; 118: 79-86.
28. Ponti G, Losi L, Pellacani G, Wannesson L, Cesinaro AM, Venesio T, et al. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer. Br J Dermatol 2008; 159: 162-168.
29. Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol 2001; 23: 308-314.
30. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001; 61: 827-830.
31. Alvino E, Passarelli F, Cannavò E, Fortes C, Mastroeni S, Caporali S, et al. High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma. Am J Clin Pathol 2014; 142: 121-132.
32. Hussein MR, Wood GS. hMLH1 and hMSH2 gene mutations are present in radial growth-phase cutaneous malignant melanoma cell lines and can be induced further by ultraviolet-B irradiation. Exp Dermatol 2003; 12: 872-875.
33. Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11: 8332-8340.
34. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
35. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816.
36. Tawbi HA, Buch SC. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 2010; 8: 259-266.
37. Rünger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 2000; 114: 34-39.
38. Meyers M, Hwang A, Wagner MW, Boothman DA. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004; 44: 249-264.
39. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994; 16: 833-839.
40. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, de Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56: 275-287.
41. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 2000; 462: 71-82.
42. Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004; 15: 421-426.
43. Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014; 3: e27817.
44. Banerjea A, Ahmed S, Hands RE, Huang F, Han X, Shaw PM, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004; 3: 21.